The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia

Abstract

To investigate the correlation between testosterone levels and lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO), to evaluate the change in testosterone secretion during treatment for LUTS, and to determine the factors that influence testosterone secretion. This was an open-labeled, single-center, prospective study of 110 outpatients with LUTS caused by benign prostatic hyperplasia. Silodosin, an alpha-1 blocker that is not known to affect testosterone secretion, was administered to the patients. Before administration and 1 year after administration, serum testosterone level was measured, and the International Prostate Symptom Score and a urodynamic study were used to assess subjective and objective symptoms. A total of 104 patients with a mean age of 70.4 years were included in the analysis. According to pretreatment evaluation, no statistically significant correlations existed between the serum total testosterone level and the International Prostate Symptom Score (r = -0.08, P = .44) or BOO index (r = 0.04, P = .68). One year after silodosin administration, the mean serum testosterone level significantly increased from 5.09 to 5.52 ng/mL (P <.001). Additionally, a significant positive correlation was observed between the change in testosterone level and improvement in the BOO index (r = 0.52, P <.001). In patients with benign prostatic hyperplasia, treatment with silodosin significantly increased testosterone secretion, and improvements in objective symptoms such as BOO were found to be the factors that influenced testosterone secretion.